Abstract
Background Early change in local intracoronary hemostasis following drug-eluting (DES) and bare metal stent (BMS) implantation has never been assessed in stable angina patients. Methods Markers of local platelet activation (soluble glycoprotein V [sGPV] and P-Selectin [CD62P]), coagulation activation (tissue factor [TF], prothrombin fragments 1 + 2 [F1 + 2] and activated factor VII [FVIIa]) and fibrinolysis markers (D-dimers [DD], fibrinogen [FIB], tissue plasminogen activator [t-PA], and plasminogen activator inhibitor type-1 complexes [PAI-1]) were determined in 20 patients with stable angina who underwent percutaneous coronary intervention (PCI). All patients were pretreated with clopidogrel, aspirin, and enoxaparin. Systematic balloon predilation was performed before DES (9 patients) and BMS (11 patients) implantation. All blood samples were drawn 10–20 mm distal to the lesion site. Results No significant changes in levels of platelet activation markers occurred during PCI. There was a transient significant increase in TF (14%; P = 0.004), in F1 + 2 (40%; P = 0.001), and FVIIa (31%; P = 0.007) following angioplasty. Similarly, a significant 43% increase was observed in DD levels following balloon predilation, associated with an increase of 46%, 60%, and 70% in FIB, t-PA and PAI-1 levels, respectively (all P < 0.0001). All these markers returned to baseline values after stent implantation. No difference was observed between DES and BMS. Conclusions Early changes in local hemostasis activation following PCI, were related to balloon predilation. Neither DES nor BMS increased markers of platelet activation, coagulation, or fibrinolysis, under dual antiplatelet and anticoagulant pretreatment.
Similar content being viewed by others
References
Chieffo A, Bonizzoni E, Orlic D, Stankovic G, Rogacka R, Airoldi F et al (2004) Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 109:2732–2736. doi:10.1161/01.CIR.0000131890.83839.5B
Alfonso F, Suarez A, Angiolillo DJ, Sabate M, Escaned J, Moreno R et al (2004) Findings of intravascular ultrasound during acute stent thrombosis. Heart 90:1455–1459. doi:10.1136/hrt.2003.026047
Scheller B, Hennen B, Pohl A, Schieffer H, Markwirth T (2001) Acute and subacute stent occlusion; risk-reduction by ionic contrast media. Eur Heart J 5:385–391. doi:10.1053/euhj.2000.2319
Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ et al (2001) Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103:1967–1971
Honda Y, Fitzgerald PJ (2003) Stent thrombosis. An issue revisited in a changing world. Circulation 108:2–5. doi:10.1161/01.CIR.0000075929.79964.D8
Nordmann AJ, Briel M, Bucher HC (2006) Mortality in randomized controlled trials comparing drug-eluting versus bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27:2784–2814. doi:10.1093/eurheartj/ehl282
Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130. doi:10.1001/jama.293.17.2126
Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667–678. doi:10.1016/S0140-6736(07)60314-6
Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS et al (2004) Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109:1930–1932. doi:10.1161/01.CIR.0000127105.99982.21
Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ (2004) A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364:583–591. doi:10.1016/S0140-6736(04)16850-5
Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT et al (2004) TAXUS-IV investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109:1942–1947. doi:10.1161/01.CIR.0000127110.49192.72
Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M et al (2005) Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45:954–959. doi:10.1016/j.jacc.2004.11.065
Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL (2005) What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis. J Am Coll Cardiol 45:941–946. doi:10.1016/j.jacc.2004.11.064
Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL (2005) Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol 95:1469–1472. doi:10.1016/j.amjcard.2005.02.015
Gyöngyösi M, Strehblow C, Sperker W, Hevesi A, Garamvölgyi R, Petrási Z et al (2006) Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: prothrombogenic response of drug-eluting or bare stent implantation within the first 24 h. Thromb Haemost 96:202–209
Babinska A, Markell MS, Salifu MO, Akoad M, Ehrlich YH, Kornecki E (1998) Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 13:3153–3159. doi:10.1093/ndt/13.12.3153
Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC et al (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115:1051–1058. doi:10.1161/CIRCULATIONAHA.106.675934
Marmur JD, Merlini PA, Sharma SK, Khaghan N, Torre SR, Israel DH et al (1994) Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 15:1484–1491
Eichinger S, Wolz M, Nieszpaur-Los M, Schneider B, Lechner K, Eichler HG et al (1994) Effects of a low molecular weight heparin (Fragmin) and of untractionated heparin on coagulation activation at the site of plug formation in vivo. Thromb Haemost 72:831–835
Weltermann A, Wolzt M, Petersmann K, Czerni C, Graselli U, Lechner K et al (1999) Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 19:1757–1760
Wendling D, Racadot E (2006) Serum tissue factor levels correlate with inflammation in ankylosing spondylitis. Joint Bone Spine 73:403–405. doi:10.1016/j.jbspin.2006.01.018
Inoue T, Hoshi K, Fujito T, Sakai Y, Morooka S, Sohma R (1996) Early detection of platelet activation after coronary angioplasty. Coron Artery Dis 7:529–534. doi:10.1097/00019501-199607000-00007
Korovesis S, Fredericks S, Holt D, Toutouzas P, Kaski JC, Webb-Peploe MM et al (2000) Release of platelet activation markers during coronary angioplasty. Coron Artery Dis 11:391–398. doi:10.1097/00019501-200007000-00003
Borries M, Heins M, Fischer Y, Stiegler H, Peters A, Reinauer H et al (1999) Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina. J Am Coll Cardiol 34:486–493. doi:10.1016/S0735-1097(99)00229-6
Shammas NW, Cunningham MJ, Pomerantz RM, Francis CW (1994) Markers of hemostatic activation in affected coronary arteries during angioplasty. Thromb Haemost 72:672–675
Philipp R, Grech ED (2003) Interventional pharmacotherapy. BMJ 327:43–46. doi:10.1136/bmj.327.7405.43
Agraou B, Corseaux D, McFadden EP, Bauters A, Cosson A, Jude B (1997) Effects of coronary angioplasty on monocyte tissue factor response in patients with stable or unstable angina. Thromb Res 88:237–243. doi:10.1016/S0049-3848(97)00234-X
Katritsis DG, Korovesis S, Giazitzoglou E, Theodorou S, Kourlaba G, Panaqiotakos D et al (2006) Direct versus predilatation drug-eluting stenting: a randomized clinical trial. J Invasive Cardiol 18:475–479
Mizuno O, Ikeda U, Hojo Y, Fujikawa H, Katsuki T, Shimada K (2001) Tissue factor expression in coronary circulation as a prognostic factor for late restenosis after coronary angioplasty. Cardiology 95:84–89. doi:10.1159/000047351
Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A (1997) Postangioplasty restenosis platelet activation and the coagulation—fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 133:387–392. doi:10.1016/S0002-8703(97)70178-9
Muldowney JA 3rd, Stringham JR, Levy SE, Gleaves LA, Eren M, Piana RN et al (2007) Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol 27:400–406. doi:10.1161/01.ATV.0000254677.12861.b8
Huber K, Jorg M, Probst P, Schuster E, Lang I, Kaindl F et al (1992) A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 67:209–213
Prisco D, Fedi S, Antonucci E, Capanni M, Chiarugi L, Chioccioli M et al (2001) Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 104:181–186. doi:10.1016/S0049-3848(01)00360-7
Maresca G, Di Blasio A, Marchioli R, Di Minno G (1999) Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 19:1368–1377
Lowe GD, Rumley A (1999) Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. Thromb Haemost 82:667–672
Sakharov DV, Kalachev LV, Rijken DC (2002) Numerical simulation of local pharmacokinetics of a drug after intravascular delivery with an eluting stent. J Drug Target 10:507–513. doi:10.1080/1061186021000038382
Kereiakes DJ, Choo JK, Young JJ, Broderick TM (2004) Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med 5:9–15. doi:10.1016/j.carrad.2004.04.002
Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Lüscher TF et al (2005) Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112:2002–2011. doi:10.1161/CIRCULATIONAHA.105.569129
Stahli BE, Camici GG, Steffel J, Akhmedov A, Shojaati K, Graber M et al (2006) Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 99:149–155. doi:10.1161/01.RES.0000233379.92010.fd
Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN (2000) Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: part I—pathophysiological and pharmacological features. Neurosurgery 46:1344–1359. doi:10.1097/00006123-200006000-00012
Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW et al (2006) Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98:352–356. doi:10.1016/j.amjcard.2006.02.039
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mahemuti, A., Meneveau, N., Seronde, MF. et al. Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents. J Thromb Thrombolysis 28, 333–341 (2009). https://doi.org/10.1007/s11239-008-0266-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-008-0266-2